Overview
Description
SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. It focuses on therapeutic areas including oncology and severe infection. The firm's marketed products include, Zadaxin. Its licensed products include Angiomax and Zometa. The company was founded on May 13, 2020 and is headquartered in Shanghai, China.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals China
Financials
Key metrics
Market capitalisation, EUR | - |
EPS, EUR | - |
P/B ratio | 3.14 |
P/E ratio | 3.22 |
Dividend yield | 0.00% |
Income statement (2023)
Revenue, EUR | 411.99 m |
Net income, EUR | 146.47 m |
Profit margin | 35.55% |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.